Sanofi Ventures reinvested in the vaccine developer through a series B round that followed a $51m series A 18 months ago.

US-based vaccine developer Icosavax completed a $100m series B round yesterday that included pharmaceutical firm Sanofi‚Äôs strategic investment arm, Sanofi Ventures. Investment manager RA Capital Management led the round, which was also backed by fellow new investors Janus Henderson Investors, Perceptive Advisors, Viking Global Investors, Cormorant Asset Management, Omega Funds, Open Philanthropy and Surveyor Capital.…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.